Document:

<PAGE>
<PAGE>
                                                    EXHIBIT 10(s)

                               SINGLE PAYMENT NOTE

$75,000,000.00                                                     July 31, 2000

     For value  received,  the Obligor  promises to pay to the order of SunTrust
Bank f/k/a SunTrust Bank,  Atlanta (the "Bank"),  on the Termination  Date, the
principal sum of

                  SEVENTY FIVE MILLION DOLLARS ($75,000,000.00)

or such  lesser  amount of loans as may from time to time,  at the  Bank's  sole
discretion,  be advanced or, upon  repayment,  readvanced by the Bank  hereunder
together with interest from the date hereof on the unpaid  principal  balance at
such  annual  rate or  rates  of  interest  as  shall  be  computed  and paid in
accordance  with the terms and conditions  hereinafter  set forth.  "Termination
Date"  shall mean the  earlier  of: (a) July 30,  2001 or such later date as the
then  existing  Termination  Date  may be  extended  by  the  Bank  in its  sole
discretion  by notice to the Obligor,  PROVIDED  that the failure of the Bank to
give such notice shall be deemed to mean that the then existing Termination Date
has not been so extended.

     This note evidences the obligation of the Obligor to repay,  with interest,
any and all present and future indebtedness of the Obligor for loans at any time
hereafter made or extended by the Bank  hereunder up to the aggregate  principal
amount of $75,000,000 at any time  outstanding.  The payment of any indebtedness
evidenced  by this note shall not affect the  enforceability  of this note as to
any future, different or other indebtedness evidenced hereby.

     The Obligor  acknowledges and agrees that Southland Life Insurance  Company
("Southland"),  Life  Insurance  Company of Georgia  ("LICG"),  ING America Life
Corporation  ("America  Life"),   Security  Life  of  Denver  Insurance  Company
("Security  Life"),  First  Columbine  Life  Insurance  Company   ("Columbine"),
Midwestern  United  Life  Insurance  Company  ("Midwestern"),   First  ING  Life
Insurance  Company of New York  ("First  ING New  York"),  United Life & Annuity
Insurance   Company   ("United   Life"),   Ameribest  Life   Insurance   Company
("Ameribest"),  Equitable Life Insurance Company of Iowa ("Equitable Life"), USG
Annuity and Life Insurance Company ("USG"), Equitable American Insurance Company
("Equitable American"),  Locust Street Securities, Inc. ("Locust Street"), First
Golden American Life Insurance Company of New York ("First  Golden"),  Equitable
of Iowa Companies, Inc. ("Equitable of Iowa"), and the Obligor are all direct or
indirect  subsidiaries  of  ING  America  Insurance  Holdings,   Inc.  ("America
Holdings") or ING Insurance  International  B.V. ("ING  International").  On the
date that this note is being executed,  Columbine,  Security Life, America Life,
Southland,  Equitable  Life,  USG, and America  Holdings are executing  separate
notes to the Bank in the maximum principal amount of $100,000,000 each; LICG and
United Life are executing a separate  note to the Bank in the maximum  principal
amount of  $75,000,000;  Equitable of Iowa is  executing a separate  note to the
Bank in the maximum principal amount of $50,000,000;  First ING New York, Locust
Street,  First Golden and Ameribest are executing  separate notes to the Bank in
the maximum  principal  amount of  $10,000,000  each;  Midwestern is executing a
separate note to the Bank in the maximum  principal  amount of $30,000,000;  and
Equitable  American  is  executing  a separate  note to the Bank in the  maximum
principal amount of $25,000,000,  each of which notes are substantially  similar
to this note (the "Affiliate  Notes").  Obligor agrees that the aggregate unpaid
principal  balance from time to time outstanding on this note plus the aggregate
unpaid  principal  balance from time to time  outstanding on the Affiliate Notes
will at no time exceed  $150,000,000.  Obligor will not request any disbursement
of principal under this note if, after such  disbursement,  the unpaid principal
balance of this note plus the aggregate  unpaid principal of the Affiliate Notes
will exceed $150,000,000.

     If the Obligor desires a disbursement of principal hereunder (an "Advance")
the Obligor  shall give the Bank written or  telephonic  notice of the amount of
such  Advance  and the period of time from one (1) day to thirty  (30) days that
such Advance shall be outstanding (the "Interest  Period"),  provided,  however,
(a) if any Interest  Period would  otherwise  end on a day which is not a day on
which the Bank and commercial banks in New York, New York, are open for business
(a "Business  Day"),  that  Interest  Period shall be extended  through the next
succeeding day which is a Business Day, and (b) no Interest  Period shall extend
beyond the Termination Date of this note. Such written or telephonic notice with
respect to the amount of an Advance  and the  Interest  Period to be  applicable
thereto  shall be  given to the Bank by the  Obligor  before  one  o'clock  p.m.
Atlanta time, on the first Business Day of the applicable  Interest Period.  All
telephonic notices shall be promptly confirmed in writing.

<PAGE>
<PAGE>

     The  Obligor  shall  pay  interest  upon  each  Advance  from  the  date of
disbursement  through the last day of the applicable  Interest Period (including
the date of  disbursement  but  excluding  the date of  repayment) at a rate per
annum,  calculated  on the basis of a 360-day year and upon the actual number of
days elapsed,  equal to either of the following rates of interest as selected by
the  Obligor:  (1) the per annum rate of interest  equal to the cost of funds of
Bank  for  the  Interest   Period   applicable   to  such  Advance  for  amounts
substantially  similar  to  the  amount  of  such  Advance  PLUS  0.225%  all as
determined by Bank in accordance  with its usual  practices in  determining  its
cost of funds  (the "Cost of Funds  Rate") or (2) a per annum  rate of  interest
that would be applicable  to the requested  Advance as quoted by the Bank to the
Obligor (the "Quoted Rate").  Unpaid  interest  accruing at either of such rates
will be due and  payable on the last  Business  Day of the  applicable  Interest
Period.  The Bank will  advise  the  Obligor  of the Cost of Funds  Rate and the
Quoted  Rate that will be  applicable  to a requested  Advance  before 1:30 p.m.
Atlanta time on the Business Day that the Bank receives a request for an Advance
from the Obligor. The Obligor will advise the Bank as to whether the Obligor has
selected the Cost of Funds Rate or the Quoted Rate before 2:00 p.m. Atlanta time
on the  Business  Day that the Bank  receives a request for an Advance  from the
Obligor. Any telephonic selection of interest rates by the Obligor will promptly
be  confirmed  in  writing.  The Bank will  promptly  disburse  the amount of an
Advance to the Obligor upon  receiving  notice of the  Obligor's  interest  rate
selection.  Unpaid  interest  accruing  at such  interest  rate  will be due and
payable on the last Business Day of the applicable Interest Period.

     The Obligor shall repay the entire  outstanding  principal  balance of each
Advance on the last Business Day of the Interest Period applicable thereto.

     The Obligor may on any  Business Day renew an  outstanding  Advance into an
Advance with the same or different Interest Period,  provided that the Bank must
be advised of the  Obligor's  election  to renew the  Advance  and the  Interest
Period  applicable to such renewal  before one o'clock p.m. on the last Business
Day of the then current Interest  Period.  The interest rate to be applicable to
the  renewal  of any  Advance  shall be  selected  in the same  manner  that the
interest rate is selected at the time an Advance is made. If no Interest  Period
has been  elected  for any  Advance  or for any  principal  balance  outstanding
hereunder,  or if such election  shall not be timely,  then the Interest  Period
with respect  thereto shall be deemed to be one day and the applicable  interest
rate shall be the Cost of Funds Rate.  NOTWITHSTANDING  THE FOREGOING,  ANY SUCH
RENEWAL SHALL BE AT THE BANK'S SOLE DISCRETION.

    No  prepayment  of any Advance  shall be  permissible  during the  Interest
Period applicable thereto.

    Should  the  Obligor  fail for any  reason  to pay this note in full on the
Termination Date or on the date of acceleration of payment,  the Obligor further
promises to pay  interest on the unpaid  amount from such date until the date of
final  payment at a Default  Rate equal to the Prime Rate plus 4%.  Should legal
action or an attorney  at law be  utilized to collect any amount due  hereunder,
the Obligor  further  promises to pay all costs of collection,  plus  reasonable
attorney's  fees.  All amounts due  hereunder may be paid at any office of Bank.
The principal balance of this note shall conclusively be deemed to be the unpaid
principal  balance  appearing  on the Bank's  records  unless  such  records are
manifestly in error.

    As security for the payment of this and any other  liability of the Obligor
to the  holder,  direct  or  contingent,  irrespective  of the  nature  of  such
liability or the time it arises,  the Obligor hereby grants a security  interest
to the holder in all  property of the Obligor in or coming into the  possession,
control  or  custody of the  holder,  or in which the  holder  has or  hereafter
acquires a lien,  security interest,  or other right. Upon default,  holder may,
without  notice,  immediately  take  possession  of and then  sell or  otherwise
dispose of the collateral, signing any necessary documents as Obligor's attorney
in fact, and apply the proceeds against any liability of Obligor to holder. Upon
demand,  the Obligor will furnish such  additional  collateral,  and execute any
appropriate  documents  related thereto,  deemed necessary by the holder for its
security.  The Obligor further authorizes the holder, without notice, to set-off
any deposit or account and apply any  indebtedness due or to become due from the
holder  to the  Obligor  in  satisfaction  of any  liability  described  in this
paragraph,  whether or not matured. The holder may, without notice,  transfer or
register  any  property  constituting  security  for this  note  into its or its
nominee name with or without any indication of its security interest therein.

<PAGE>
<PAGE>

     This note shall  immediately  mature and  become due and  payable,  without
notice or demand, upon the appointment of a receiver for the Obligor or upon the
filing of any petition or the  commencement of any proceeding by the Obligor for
relief  under any  bankruptcy  or  insolvency  laws,  or any law relating to the
relief of debtors,  readjustment  of  indebtedness,  debtor  reorganization,  or
composition or extension of debt. Furthermore, this note shall, at the option of
the holder,  immediately  mature and become due and payable,  without  notice or
demand,  upon the  happening  of any one or more of the  following  events;  (1)
nonpayment  on the due date of any  amount  due  hereunder;  (2)  failure of the
Obligor to perform  any other  material  obligation  to the  holder;  (3) if the
Obligor  shall fail to make any payment as and when such payment is due upon any
obligation for borrowed  money other than the obligation  owing pursuant to this
Note,  and by reason  thereof  such  obligation  becomes due prior to its stated
maturity or prior to its regularly scheduled dates of payment;  (4) a reasonable
belief  on the  part  of the  holder  that  the  Obligor  is  unable  to pay its
obligations when due or is otherwise  insolvent;  (5) the filing of any petition
or the  commencement  of any  proceeding  against the  Obligor for relief  under
bankruptcy  or  insolvency  laws,  or any law relating to the relief of debtors,
readjustment of indebtedness, debtor reorganization, or composition or extension
of debt,  which  petition or proceeding  is not dismissed  within 60 days of the
date of filing  thereof;  (6) the  suspension  of the  transaction  of the usual
business of the Obligor, or the dissolution,  liquidation or transfer to another
party of a significant  portion of the assets of the Obligor and any such action
shall have a material  adverse effect on the ability of the Obligor to repay the
unpaid  principal  balance  hereof;  (7) a reasonable  belief on the part of the
holder that the Obligor has made a representation or warranty in connection with
any loan by or other  transaction  with the  holder and such  representation  or
warranty  was false in any material  respect;  (8) the issuance or filing of any
levy, attachment, garnishment, or lien against the property of the Obligor which
shall remain  unpaid or  undischarged  for a period of thirty (30) days and such
failure  to pay shall  have a  material  adverse  effect on the  ability  of the
Obligor to repay the unpaid  principal  balance  hereof;  (9) the failure of the
Obligor  to  satisfy  any  judgment,  penalty  or fine  imposed  by a  court  or
administrative  agency of any  government and such  judgment,  penalty,  or fine
shall remain  unpaid,  unstayed on appeal,  undischarged  or  undismissed  for a
period of thirty  (30) days;  (10)  failure of the  Obligor,  after  demand,  to
furnish  financial  information or to permit  inspection of any books or records
during Obligor's  normal business hours;  (11) Equitable of Iowa shall no longer
own 100% of the  outstanding  voting stock of the  Obligor,  or (12) the Obligor
shall fail to maintain  the  minimum  level of Company  Action  Level Risk Based
Capital as established by applicable state law or regulation.

     The failure or forbearance  of the holder to exercise any right  hereunder,
or otherwise  granted by law or another  agreement,  shall not affect or release
the  liability of the Obligor,  and shall not  constitute a waiver of such right
unless so stated by the holder in writing.  The  Obligor  agrees that the holder
shall have no  responsibility  for the  collection or protection of any property
securing  this note,  and  expressly  consents  that the holder may from time to
time,  without  notice,  extend the time for  payment of this note,  or any part
thereof,  waive its rights with respect to any property or indebtedness  without
releasing the Obligor from any liability to the holder. This note is governed by
Georgia law.

     The term "Obligor" means Golden American Life Insurance  Company.  The term
"Prime  Rate",  if used herein,  shall mean that rate of interest  designated by
Bank from time to time as its "Prime  Rate"  which rate is not  necessarily  the
Bank's best rate. The term "holder" means Bank and any subsequent  transferee or
endorsee hereof.

             PRESENTMENT AND NOTICE OF DISHONOR ARE HEREBY WAIVED BY THE OBLIGOR

                                          GOLDEN AMERICAN LIFE INSURANCE COMPANY

                                     By:/s/ David S. Pendergrass
                                        ----------------------------------------
                                        Name: David S. Pendergrass
                                        Title: Vice President and Treasurer

<PAGE>
<PAGE><PAGE>   1

                                                                    EXHIBIT 10.1

                          EXCLUSIVE LICENSE AGREEMENT

        THIS AGREEMENT, effective as of the first day of May 1995 (hereinafter
"Effective Date"), by and between CORNELL RESEARCH FOUNDATION, INC., having
offices at Cornell Business & Technology Park, 20 Thornwood Drive, Suite 105,
Ithaca, New York 14850, hereinafter referred to as "FOUNDATION" and EDEN
BIOSCIENCE CORPORATION, having offices at 5795 N.E. Minder, Poulsbo, Washington
98370, hereinafter referred to as "LICENSEE".

                         W I T N E S S E T H  T H A T:

        WHEREAS, United States Patent Application No. 08/200,724, entitled
"Elicitors of the Hypersensitive Response in Plants" (CRF D-1172), was filed in
the U.S. Patent & Trademark Office on February 2, 1994, a copy of which is
appended as Exhibit A and Patent Application No. 08/200,724 is a continuation of
U.S. Patent Application No. 07/907,935 filed on 1 September 1992 and the foreign
equivalent PCT/US93/06243 was filed on 30 June 1993 covering all EPC countries
and Japan; and

        WHEREAS, United States Patent Application No. 08/062,024, entitled
"Pseudomonas Syringae pv. syringae hrpz Gene (CRF D-1425), was filed in the U.S.
Patent & Trademark Office on 17 May 1993, a copy of which is appended as Exhibit
B and the foreign equivalent PCT/US94/05014 was filed on 5 May 1994 covering all
EPC countries and Japan; and

        WHEREAS, FOUNDATION intends to file a United States Patent Application
entitled "Harpin-Induced Systemic Acquired Resistance (SAR) to Plant Pathogens,"
now Invention Disclosure CRF D-1654, a copy of which is appended as Exhibit C,
and FOUNDATION intends to file foreign equivalents, where appropriate, of said
Invention Disclosure; and

        WHEREAS, FOUNDATION intends to file a United States Patent Application
entitled "Erwina chrysanthemi Elicitor of the Hypersensitive Response in
Plants," now Invention Disclosure CRF D-1732, a copy of which is appended as
Exhibit D, and FOUNDATION intends to file foreign equivalents, where
appropriate, of said Invention Disclosure; and

        WHEREAS, the inventions disclosed and claimed in Exhibits A, B, C and D
are, or will be assigned to FOUNDATION and FOUNDATION is a wholly owned
subsidiary corporation of Cornell University and holds the ownership interests
of patents issued on inventions made by Cornell University's staff and
administers licenses in a manner consistent with the patent policy of Cornell
University; and

        WHEREAS, FOUNDATION represents that it is, or will be assignee of the
above-identified patent applications and any patents issuing thereon and has the
right to grant licenses under said patent applications and patents issuing
thereon; and

        WHEREAS, the work leading to the inventions disclosed and to be claimed
in Exhibits A, B, C and D were supported in part by an agency of the U.S.
Government,

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 1

<PAGE>   2

FOUNDATION is obligated to comply with the U.S. Office of Management & Budgets
Circular No. A-124, or 37 CFR Part 401; and

        WHEREAS, Drs. Steven Beer, Alan Collmer and their colleagues at Cornell
University have developed proprietary biological materials and processes
relating to the field of plant disease and some of these materials and processes
are or will be claimed and covered in said patent applications of Exhibits A, B,
C and D and other such materials and processes are not claimed in said patent
applications but are proprietary to FOUNDATION; and

        WHEREAS, LICENSEE is desirous of securing a license under the
discoveries and inventions embodied in said patent applications and patents
issuing thereon as well as the discoveries and inventions embodied in said
related proprietary biological processes and materials to make, have made, use
and sell Licensed Products in the United States and throughout the world; and

        WHEREAS, FOUNDATION is willing to grant a license in said patent
applications and any patents issuing thereon as well as the discoveries and
inventions embodied in said related proprietary biological processes and
materials to LICENSEE upon the terms and conditions hereinafter set forth; and

        NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth, the parties hereto hereby agree as follows:

I.      DEFINITIONS

        The following definitions will apply throughout this agreement:

        1. Licensed Patent Application shall mean U.S. Patent Application Serial
No. 08/200,724 attached as Exhibit A and any continuation, continuation-in-part,
or divisional applications thereof as well as foreign counterparts thereof and
U.S. Patent Application Serial No. 08/062,024 attached as Exhibit B and any
continuation, continuation-in-part, or divisional applications thereof as well
as foreign counterparts thereof and any U.S. Patent Application based on
Invention Disclosure CRF D-1654 attached as Exhibit C and any continuation,
continuation-in-part, or divisional applications thereof as well as foreign
counterparts thereof and any U.S. Patent Application based on Invention
Disclosure CRF D-1732 attached as Exhibit D and any continuation,
continuation-in-part, or divisional applications thereof as well as foreign
counterparts thereof.

        2. Licensed Patent shall mean any U.S. Patents issuing from a Licensed
Patent Application, and all reissues thereof as well as foreign counterparts
thereof.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 2

<PAGE>   3

        3. Licensed Biological Material shall mean that biological material
including genes, proteins and peptide fragments, expression systems, cells and
antibodies developed in the Cornell University Laboratories of Drs. Steven Beer,
Alan Collmer and their colleagues and which is directly related to the
inventions described in Licensed Patents or Licensed Patent Applications and
which is listed and described in Exhibit E or added to Exhibit E at a later time
by written mutual agreement of the parties.

        FOUNDATION and LICENSEE acknowledge that, to the best of their
knowledge, said list of Exhibit E is complete.

        4. Licensed Products shall mean any product or use claimed in a Licensed
Patent Application or Licensed Patent or any product or use which incorporates
or otherwise utilizes Licensed Biological Material.

        5. License Year shall mean each twelve (12) month period beginning on
the Effective Date of this Agreement first written above and thereafter on the
anniversary date thereof.

        6. LICENSEE shall mean the above named company and any of its affiliates
in which it owns or controls at least 50% of the voting stock.

        7. Net Sales Price shall mean [*].

II.     GRANT

        Subject only to the rights of and obligations to the U.S. Government as
set forth in U.S. Office of Management & Budget Circular A-124 or 37 CFR Part
401;

        The FOUNDATION hereby grants to the LICENSEE for the term set forth
below and under the royalty basis set forth below, an exclusive license to the
Licensed Patent Applications, Licensed Patents and Licensed Biological Materials
to make, have made, use and sell Licensed Products in the United States and
throughout the world. The term "exclusive license" as used hereinabove shall
mean that FOUNDATION shall not issue a license to another, within the period of
exclusivity set forth hereinafter or any agreed upon extension thereof.
FOUNDATION shall not make, have made, use or sell Licensed Products. Cornell
University researchers shall

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 3

<PAGE>   4

retain the royalty-free right to use Licensed Patent Applications, Licensed
Patents and Licensed Biological Materials for internal research purposes and
such use shall not prohibit such researchers from producing inventions and, if
such inventions are made solely by said Cornell University researchers, such
inventions shall be the property of FOUNDATION. If such inventions are made
jointly by said Cornell University researchers and employees of LICENSEE, such
inventions shall be the joint property of FOUNDATION and LICENSEE.

III.    TO HAVE MADE

        The right of LICENSEE to make Licensed Products includes the right to
have made by contract with third parties within a country where LICENSEE is
licensed and patent protection for Licensed Products exists or is pending. Such
contractual arrangements with third parties shall be subject to and conditioned
upon appropriate supervision and quality assurance and control of the third
party by LICENSEE and the third party shall respect all rights of FOUNDATION and
to supply all production of Licensed Products exclusively to LICENSEE or its
designee(s).

IV.     PAYMENTS MADE IN CONSIDERATION OF THE EXECUTION OF THIS LICENSE
        AGREEMENT

        FOUNDATION hereby acknowledges a payment, due upon approval of this
Agreement by the Board of Directors of FOUNDATION (or at least by the Executive
Committee of that Board), of four hundred thousand (400,000) equity shares of
common stock in LICENSEE which amount equals seven and fourteen hundredths
percent (7.14%) of LICENSEE'S total issued stock as of Effective Date, made by
LICENSEE as a consideration for entering into this Agreement, which sum will not
be considered as an advance payment on royalties due hereunder. It is understood
by the parties that said equity shares in LICENSEE held by FOUNDATION shall be
non-voting and FOUNDATION shall take no management role in LICENSEE.

        If said approval by the Board of Directors of FOUNDATION is not obtained
within six (6) months of the Effective Date, FOUNDATION and LICENSEE agree to
renegotiate alternative financial terms as consideration for entering into this
Agreement.

        The parties acknowledge that LICENSEE may, upon termination of this
Agreement, cancel said equity shares according to the following schedule:

        1)      Upon termination of this Agreement at any time up to [*] from
                the Effective Date, LICENSEE may cancel up to [*] of the total
                equity

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 4

<PAGE>   5

                shares which were issued to FOUNDATION and approved by
                FOUNDATION'S Board of Directors.

        2)      Upon termination of this Agreement at any time from [*] from
                the Effective Date up to [*], LICENSEE may cancel up to [*]
                of the total equity shares which were issued to FOUNDATION and
                approved by FOUNDATION'S Board of Directors.

        3)      Upon termination of this Agreement at any time from [*] until
                [*] LICENSEE may cancel up to [*] of the total equity shares
                which were issued to FOUNDATION and approved by FOUNDATION's
                Board of Directors.

        4)      Upon termination of this Agreement at any time from [*] to
                [*], LICENSEE may cancel up to [*] of the total equity
                shares which were issued to FOUNDATION and approved by
                FOUNDATION'S Board of Directors.

        5)      Upon termination of this Agreement at any time from [*] to
                [*], LICENSEE may cancel up to [*] of the total equity
                shares which were issued to FOUNDATION and approved by
                FOUNDATION'S Board of Directors.

        6)      Upon termination of this Agreement at any time after [*]
                LICENSEE may not cancel any of the total equity shares which
                were issued to FOUNDATION and approved by FOUNDATION'S Board of
                Directors.

        As additional consideration, LICENSEE will fund research activity in the
Cornell University laboratories of Dr. Steven Beer and his colleagues at a level
not less than [*] in License Year 1 and [*] in each of License Year 2 and
License Year 3. Said funding shall be contingent upon a mutually agreed workplan
and budget for said research activity and such amounts are inclusive of all
costs including direct and indirect costs.

        Any inventions made using the research funding, described above,
provided to Dr. Beer and his colleagues by LICENSEE which are dominated by the
claims of Licensed Patent Applications or Licensed Patents shall, to the extent
possible considering FOUNDATION'S obligations to third parties, be subject to
the terms and conditions of this Agreement and shall be included herein by
letter amendment to this Agreement.

        Any inventions made using the research funding provided to Dr. Beer by
LICENSEE which are not dominated by the claims of Licensed Patent Applications
or

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 5

<PAGE>   6

Licensed Patents shall not be subject to the terms and conditions of this
Agreement. FOUNDATION shall provide LICENSEE the first opportunity to negotiate
to obtain an exclusive license in such inventions and will not offer any third
party any license having more favorable terms and conditions unless those terms
and conditions have first been offered to and refused by LICENSEE.

V.      FOREIGN PATENTS AND PAYMENT OF COSTS

        As the opportunity to continue prosecution of foreign counterpart
applications of United States Patent Applications No. 08/200,724 and No.
08/062,024 and to file foreign counterpart applications on the U.S. patent
applications to be filed on Invention Disclosures CRF D-1654 and CRF D-1732
exists, LICENSEE may designate foreign countries where counterpart applications
shall be filed. Title to such foreign patent applications shall be in
FOUNDATION. LICENSEE agrees to pay for all expenses incurred in the preparation,
filing, prosecution, renewal and continuation of Licensed Patents and Licensed
Patent Applications in said designated countries including all taxes, official
fees and attorney's fees, as well as a [*] administrative fee assessed by
FOUNDATION. Notwithstanding the foregoing, LICENSEE may elect in writing to be
released from its license in any of the Licensed Patents and Applications in
foreign countries at any time after initial filing costs have been paid, in
which event it shall thereafter have no obligation to reimburse FOUNDATION for
any future expenses relating to such patent or patent application. Upon approval
of this Agreement by the FOUNDATION's Board of Directors, LICENSEE shall
reimburse FOUNDATION for all direct and documentable foreign patent costs
incurred to date, plus said [*] administrative fee assessed by FOUNDATION.

VI.     PAYMENT OF U.S. PATENT COSTS

        Where renewal fees are due on a Licensed Patent in the United States and
LICENSEE remains exclusively licensed or is the sole nonexclusive licensee,
LICENSEE agrees to reimburse FOUNDATION for the costs of said renewal within
thirty (30) days of Notice thereof to LICENSEE by FOUNDATION.

        Where Licensed Patent Applications are pending in the United States
LICENSEE agrees to pay all direct and documentable prosecution costs for such
Licensed Patent Applications at least through an appeal to the U.S. Patents &
Trademark Office Board of Appeals plus a [*] administrative fee assessed by
FOUNDATION.

        Notwithstanding the foregoing, LICENSEE may elect in writing to be
released from its license in any of the Licensed Patents and Applications in the
United States at any time after initial filing costs have been paid, in which
event it shall thereafter have

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 6

<PAGE>   7

no obligation to reimburse FOUNDATION for any future expenses relating to such
patent or patent application.

        Upon approval of this Agreement by FOUNDATION's Board of Directors,
LICENSEE shall reimburse FOUNDATION for all direct and documentable costs
related to Licensed U.S. Patent Applications incurred to date, plus a [*]
administrative fee assessed by FOUNDATION; such amount, including equivalent
Foreign Patent costs described hereinabove is expected to approximate [*] as
of the Effective Date.

VII.    PATENT PROSECUTION MANAGEMENT

        The parties acknowledge the importance of cooperating on the ongoing
management of prosecution of Licensed Patent Applications. FOUNDATION agrees to
utilize patent counsel selected by FOUNDATION and reasonably approved by
LICENSEE for the purpose of filing and prosecuting Licensed Patent Applications.
FOUNDATION further agrees to consult with LICENSEE in a timely manner concerning
(i) the scope and content of Licensed Patent Applications (ii) the strategy and
tactics of patent prosecution, (iii) content of proposed responses to official
actions of the United States Patent and Trademark Office and foreign patent
offices during prosecution of such patent applications and (iv) cost of patent
prosecution. For purposes of this paragraph, "timely shall mean whenever
possible, sufficiently in advance of any patent prosecution decision by the
FOUNDATION so as to allow LICENSEE to meaningfully review such decision or
written response and provide comments to FOUNDATION in advance of such decision
or deadline so that LICENSEE's comments can be considered and incorporated into
FOUNDATION's decision or written response.

        Additionally, it is FOUNDATION's intent to transfer responsibility for
management of patent prosecution and maintenance activity on Licensed Patent
Applications and Licensed Patents to LICENSEE two (2) years from the Effective
Date. Such transfer shall be contingent upon LICENSEE's agreement to utilize
patent counsel selected by LICENSEE and reasonably approved by FOUNDATION for
the purpose of filing and prosecuting Licensed Patent Applications and
maintaining Licensed Patents. Upon such transfer, LICENSEE shall further agree
to consult with FOUNDATION in a timely manner concerning (i) the scope and
content of Licensed Patent Applications (ii) the strategy and tactics of patent
prosecution and (iii) content of proposed responses to official actions of the
United States Patent and Trademark Office and foreign patent offices during
prosecution of such patent applications. For purposes of this paragraph,
"timely" shall mean sufficiently in advance of any patent prosecution decision
by the LICENSEE so as to allow FOUNDATION to meaningfully review such decision
or written response and provide comments to

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 7

<PAGE>   8

LICENSEE in advance of such decision or deadline so that FOUNDATION's comments
can be considered and incorporated into LICENSEE's decision or written response.
Such transfer shall also be contingent upon LICENSEE's demonstration to
FOUNDATION that it can and will comply with the following:

        a)      all documents related to the prosecution of Licensed Patent
                Applications shall show Cornell Research Foundation as the
                Assignee of record;

        b)      LICENSEE shall ensure that FOUNDATION be provided copies of all
                correspondence and documents related to said patent prosecution
                and maintenance management;

        c)      LICENSEE shall ensure that all maintenance fees on all Licensed
                Patents be paid and that in no event shall Licensed Patents be
                allowed to lapse for failure to pay such fees without the
                concurrence of FOUNDATION on such lapse.

        Although it is FOUNDATION's intention to allow LICENSEE to continue said
responsibility for patent prosecution and maintenance for the duration of this
exclusive license Agreement, FOUNDATION reserves the right to reassume such
responsibility if it can show that LICENSEE's efforts are insufficient in
carrying out such activities.

        Should the exclusive license granted hereunder to LICENSEE become
non-exclusive, FOUNDATION shall have the responsibility for filing, prosecuting
and maintaining all Licensed Patent Applications and Licensed Patents at its own
expense.

VIII.   ROYALTIES AND MINIMUM ROYALTIES TO BE PAID DURING THE LICENSE AGREEMENT

        LICENSEE will pay to the FOUNDATION a royalty of [*] of the Net Sales
Price of Licensed Products made, used or sold by LICENSEE in the United States
and throughout the world.

        LICENSEE'S obligation to pay the [*] royalty rate upon each such
product shall cease in a particular country:

                (i)     if the applicable claims in the Licensed Patent in any
                        particular country are held invalid by an unappealed or
                        unappealable decision of a court of competent
                        jurisdiction in that particular country, or

                (ii)    upon expiration of the last said Licensed Patent; or

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 8

<PAGE>   9

                (iii)   if FOUNDATION abandons its patent solicitation efforts
                        for all Licensed Patent Applications and no Licensed
                        Patent is in force.

        Provided however, should no Licensed Patent issue and all Licensed
Patent Applications are abandoned but LICENSEE utilizes a Licensed Biological
Material to make, use or sell Licensed Products, LICENSEE will pay to FOUNDATION
a royalty of [*] of the Net Sales Price of Licensed Products made, used or
sold by LICENSEE in the United States and throughout the world.

        Beginning with the fifth License Year, each License Year LICENSEE shall
pay FOUNDATION a minimum annual royalty payment according to the following
schedule:
               [*]

        Such payments shall be made quarterly throughout the License Year and
such moneys will be considered as a credit for the royalties due for that
License Year under this Agreement and the royalty reports should reflect the use
of such credit. Such provision is to be construed as an annual minimum royalty
payment requirement and none of the minimum royalty payments are refundable or
applicable to succeeding License Years.

        In License Years 5, 6 and 7, LICENSEE may credit the direct and
documentable costs it has expended on research and development of transgenic
organism applications of Licensed Patent Applications and Licensed Patents
against up to [*] of minimum annual royalties owed for those License Years.

        In the event LICENSEE is required to pay royalties to a third party in
order to make, use or sell Licensed Products, FOUNDATION shall review the
minimum annual royalty payment obligation described hereinabove and agrees to
negotiate in good faith with LICENSEE to make adjustments in such payment
obligations.

        In any event, sales from non-transgenic plant applications must
constitute at least [*] of the total minimum annual royalty payment
obligation.

        In the event that this Agreement is converted to a field-of-use
exclusive license, non-exclusive license or semi-exclusive license in the field
of transgenic organisms according to the "TERM" (IX) and "DUE DILIGENCE" (X)
Sections hereinbelow, the minimum annual royalty payments described hereinabove
shall be reduced by [*].

        It is acknowledged and agreed that the minimum annual royalty payment
shall be allocated between the field of non-transgenic applications and the
field of transgenic organisms in the ratio of [*] of the minimum annual
royalty payment is

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                          PAGE 9

<PAGE>   10

allocated to the field of non-transgenic applications and [*] is allocated to
the field of transgenic organisms) and the sole remedy of FOUNDATION for
nonpayment of either portion of such minimum annual royalty payment shall be
(after notice of such nonpayment and opportunity to cure) termination of the
license rights for the field of use to which the portion of the payment applies.

IX.     FAVORED NATIONS

        If FOUNDATION grants a non-exclusive license to others under a Licensed
Patent Application or Licensed Patent, such licenses will not be granted at a
royalty rate which is more favorable than the rate herein granted to LICENSEE
unless such more favorable rates are extended to LICENSEE. This Favored Nations
clause does not apply to license agreements which are in settlement of patent
litigation.

X.      ACCOUNTING AND PAYMENT SCHEDULE

        Payment, reporting and financial accounting shall be on a quarterly
basis and LICENSEE will deliver to the FOUNDATION within ninety (90) days after
the end of each quarter of the License Year a report in writing setting forth
sales of Licensed Products (including a negative report if appropriate) and will
accompany such report with an appropriate payment of royalty or minimum royalty
due for such period. LICENSEE will keep accurate records, certified by it,
showing the information by which LICENSEE arrived at a royalty determination and
will permit a person appointed by the FOUNDATION and acceptable to LICENSEE to
make such inspection of said records as may be necessary to verify royalty
reports made by LICENSEE.

        Conversion from foreign currencies, if any, shall be based upon the
conversion rate on the date that payment in due.

        Payments which are delayed beyond the sixty (60) days after the end of
the quarter in which they become due shall be subject to a [*] per annum
interest charge.

XI.     TERM

        The aforesaid exclusive license under Licensed Patent Applications,
Licensed Patents and Licensed Biological Material shall last for a period ending
on the expiration date of the last to expire Licensed Patent or, should only
Licensed Biological Materials be licensed, then for a period of fifteen (15)
years from the date of this Agreement.

        By mutual agreement of FOUNDATION and LICENSEE, this Agreement may be
converted into a field-of-use exclusive license. Said field-of-use exclusive
license

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 10

<PAGE>   11

would only rescind LICENSEE's rights to make, use and sell Licensed Products in
the field of transgenic organisms.

XII.    DUTY OF DILIGENCE

        LICENSEE shall exercise reasonable due diligence to affect the
introduction of Licensed Products into the commercial market as soon as
practical. LICENSEE agrees to develop and exploit Licensed Products with
reasonable diligence by manufacture and sale of Licensed Products for the
duration of the term of this Agreement. LICENSEE further agrees to maintain
quality control over Licensed Products and generally attend to proper, safe,
fair, lawful and reasonable development and exploitation of the market for
Licensed Products. Failure of LICENSEE to materially comply with the provisions
of this Paragraph shall be considered a material breach of this Agreement.

        LICENSEE's reasonable due diligence obligations shall include the
expressed pursuit to affect introduction of Licensed Products into the field of
transgenic organisms. In order for LICENSEE to retain the exclusive license in
the field of transgenic organisms, LICENSEE must accomplish one of the following
within [*] of the Effective Date:

        [*]

        [*]

        [*]

        In the event LICENSEE fails to accomplish at least one of the
alternatives described above, FOUNDATION may, at its sole discretion, convert
this Agreement to a field-of-use exclusive license which shall wholly rescind
LICENSEE's rights to make, use and sell Licensed Products in the field of
transgenic organisms. Alternatively, in the event LICENSEE fails to accomplish
at least one of the alternatives described above, FOUNDATION may, at its sole
discretion, convert this Agreement to a non-exclusive or semi-exclusive license
in the field of transgenic organisms. In the event of such conversion from
exclusive to said field-of-use exclusive or non-exclusive or semi-exclusive
license, FOUNDATION shall be free to license others in the field of transgenic
organisms.

XIII.   INFRINGEMENT OF LICENSED PATENT RIGHTS BY THIRD PARTIES

        In the event that any infringement of a Licensed Patent shall come to
the attention of the FOUNDATION or LICENSEE, then FOUNDATION and LICENSEE

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 11

<PAGE>   12
shall duly inform each other. FOUNDATION, shall, in its sole discretion
determine whether or not to prosecute a patent infringement action. If
FOUNDATION determines and elects not to prosecute a patent infringement action,
then LICENSEE may cause legal proceedings against the alleged infringer at its
own expense and in the name of FOUNDATION, if necessary, if there is a showing
of substantial likelihood of infringement and that no other action for
infringement is pending at the time so that only one such lawsuit is pending at
any time.

        LICENSEE may defray the expenses of any such lawsuit to the extent of
[*] of royalties payable by LICENSEE during the course of and directly related
to such legal proceedings. Out of any damages or awards recovered by LICENSEE in
such action conducted by LICENSEE, LICENSEE will first recover its expenses for
conducting said litigation beyond the costs defrayed by withheld royalties.
FOUNDATION will then recover all royalties up to the [*] of royalties payable by
LICENSEE to FOUNDATION and withheld by LICENSEE to defray costs of such lawsuit.
FOUNDATION will also recover any expenses which it incurred on behalf of the
litigation. Any amount remaining belongs to LICENSEE, if LICENSEE conducts the
litigation, provided that on such amount LICENSEE shall pay FOUNDATION a royalty
as provided for in VIII above. If FOUNDATION conducts the litigation, at its own
expense, out of any amount recovered, FOUNDATION shall first recover any
expenses which it incurred on behalf of the litigation, next LICENSEE shall
recover direct and documentable losses including opportunity costs caused by
said infringement and any amount remaining shall belong to FOUNDATION.

        In any proceedings, FOUNDATION shall be entitled to employ, at its own
expense, counsel and control the course of litigation if, in FOUNDATION's sole
discretion, LICENSEE's defense of patent rights is insufficient, or if LICENSEE
fails to carry on vigorous prosecution of said patent rights.

        In the event LICENSEE seeks, with justifiable cause, to prosecute more
than one lawsuit at a time, FOUNDATION will not unreasonably withhold permission
where such actions are conducted entirely at LICENSEE's expense including
reimbursement of FOUNDATION's expenses incurred on behalf of such action.

        In any action brought by LICENSEE, LICENSEE undertakes to indemnify for
and hold FOUNDATION harmless from any damages, costs or expenses incurred by
reason of such litigation.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 12

<PAGE>   13

XIV.    ASSIGNMENT

        The rights and obligations of the LICENSEE are not assignable but with
one exception which is that those rights and obligations may be assigned in
connection with the sale of all or substantially all of the assets of LICENSEE
to a third party.

XV.     SUBLICENSING

        LICENSEE may grant sublicenses under Licensed Patent Applications,
Licensed Patents and Licensed Biological Material with prior approval of
FOUNDATION, which approval shall not be withheld unless FOUNDATION can show a
substantial likelihood that such sublicensee would not perform its obligations
under sublicense agreement or that the sublicensee is an organization of a
character such that FOUNDATION and Cornell University may encounter a
substantial risk of substantial, long term and public criticism as a public
institution for providing its proprietary technology to such an organization,
e.g. more than internal student and/or faculty protestors and likely to cause
long term problems. Upon written notification of FOUNDATION by LICENSEE of its
intent to sublicense, FOUNDATION shall have thirty (30) days within which to
notify LICENSEE of FOUNDATION's disapproval of such sublicense and to provide
the reasons of such disapproval, after which such approval shall be deemed
given. LICENSEE agrees that said sublicensees are obligated in writing to all
terms and conditions of this Agreement beneficial to or protective of FOUNDATION
and that LICENSEE shall guarantee compliance of the sublicense on all such
provisions.

        Sublicense royalty income may be credited against LICENSEE's minimum
annual royalty payment obligations described in "ROYALTIES . . . Section VII,
hereinabove.

XVI.    TERMINATION

        In the event FOUNDATION finds LICENSEE to be in substantial
noncompliance with any of the material terms and conditions of this Agreement,
FOUNDATION shall so notify LICENSEE in writing. LICENSEE shall have six months
after receipt of such notification within which to remedy such noncompliance to
the satisfaction of FOUNDATION. If LICENSEE does not remedy a material
noncompliance within said six month period, FOUNDATION may terminate this
License Agreement. Upon giving such notice, LICENSEE shall have no obligations
for minimum royalties, patent expenses or research funding beyond the
termination date.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 13

<PAGE>   14

        LICENSEE may terminate this License Agreement by giving notice of its
intentions to do so six (6) months before termination.

        Upon termination of this Agreement, any sublicensee that is not then in
material breach shall have its sublicense converted to a direct license from
FOUNDATION under the terms and conditions of this Agreement, as further limited
and restricted by the terms of the original sublicense.

XVII.   ARBITRATION AND JURISDICTION

        All disputes over the meaning and interpretation of this Agreement shall
be resolved by conciliation and mediation and if mediation is unsuccessful then
disputes shall be finally settled by an Arbitrator selected by FOUNDATION and
LICENSEE. If FOUNDATION and LICENSEE cannot agree on an Arbitrator, then
disputes shall be resolved by an Arbitration Panel comprising one arbitrator
appointed by FOUNDATION, one arbitrator appointed by LICENSEE, and a Chairman of
the Arbitration Panel appointed by the first two arbitrators. Any such
arbitration proceeding shall be conducted in accordance with generally accepted
arbitration rules; shall be held in the State of New York, unless otherwise
agreed by the parties; and judgment upon the arbitration award may be entered in
any court having jurisdiction.

        In order to initiate procedures for dispute resolution by conciliation,
mediation and arbitration either party may give written notice to the other of
intention to resolve a dispute, and absent satisfactory resolution, then to
arbitrate. Such notice shall contain a statement setting forth the nature of the
dispute and the resolution sought. If, within thirty (30) days of such notice a
resolution by conciliation between the parties themselves or by mediation has
not been achieved to the satisfaction of both parties, and if within sixty (60)
days from said written notice an Arbitrator or Arbitration Panel has not been
appointed with an arbitration schedule satisfactory to both parties, then either
party may proceed with judicial remedies.

        The FOUNDATION reserves the right and power to proceed with direct
judicial remedies against LICENSEE without conciliation, mediation or
arbitration for breach of the royalty payment and sales reporting provisions of
this Agreement after giving written notice of such breach to LICENSEE followed
by an opportunity period of thirty (30) days in which to cure such breach. In
collecting overdue royalty payments and securing compliance with reporting
obligations, FOUNDATION may use all judicial remedies available.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 14

<PAGE>   15

XVIII.  OTHER

        LICENSEE agrees that it will not use the indicia or names FOUNDATION or
of Cornell University or any of their personnel in advertising, promotion, or
labeling of Licensed Products without prior written approval of the FOUNDATION.

        Title to all Licensed Biological Materials remains with FOUNDATION and
LICENSEE's rights in Licensed Biological Materials is by way of bailment with
rights sufficient to carry out the purposes of this Agreement. Upon termination
of this Agreement for cause by FOUNDATION, LICENSEE shall return all Licensed
Biological Materials, progeny and derivatives thereof, in whatever form, to
FOUNDATION or certify their destruction, at the option of FOUNDATION. Upon the
natural termination of this Agreement, LICENSEE may continue to use Licensed
Biological Materials without accounting to or recourse by FOUNDATION.

        FOUNDATION makes no representations other than those specified in the
WHEREAS clauses. FOUNDATION MAKES NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

        FOUNDATION by this Agreement makes no representation as to the
patentability and/or breadth of the inventions and/or discoveries involved in a
Licensed Patent. FOUNDATION by this Agreement makes no representation as to
patents now held or which will be held by others in the field of the Licensed
Products for a particular purpose.

        LICENSEE agrees to defend, indemnify and hold FOUNDATION harmless from
and against all liability, demands, damages, expenses or losses for death,
personal injury, illness or property damage (including reasonable attorney's
fees) arising (a) out of use by LICENSEE or its transferees of inventions
licensed or information furnished under this Agreement, or (b) out of any use,
sale or other disposition by LICENSEE or its transferees of products made by use
of such inventions or information. As used in this clause, "FOUNDATION" includes
its Trustees, Officers, Agents and Employees, and those of Cornell University,
and "LICENSEE" includes its Affiliates, Subsidiaries, Contractors and
Sub-Contractors.

        In discharge of the above and with respect to Licensed Products,
LICENSEE shall secure and maintain product liability insurance commensurate with
the reasonable standards of the industry. Upon written request from FOUNDATION,
LICENSEE shall provide FOUNDATION with evidence of such insurance coverage.

        This Agreement shall be interpreted under the Laws of the State of New
York.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 15

<PAGE>   16

        Reports, notices and other communications to the FOUNDATION shall be
addressed to:

               H. Walter Haeussler, President
               CORNELL RESEARCH FOUNDATION, INC.
               Cornell Business & Technology Park
               20 Thornwood Drive, Suite 105
               Ithaca, New York 14850

and notices and other communications to the LICENSEE to:

               Jerry L. Butler, President
               Eden Bioscience Corporation
               5795 N.E. Minder
               Poulsbo, Washington 98370

        IN WITNESS WHEREOF, the parties have caused this instrument to be
executed in duplicate as of the day and year first above written.

ATTEST:                                   CORNELL RESEARCH FOUNDATION, INC.

                                          By      /s/ H. Walter Haeussler
---------------------------------               --------------------------------
                                                  H. Walter Haeussler
                                          Title   President
                                                --------------------------------
                                          Date
                                                --------------------------------
ATTEST:

                                          By      /s/ Jerry L. Butler
                                                --------------------------------
                                                  Jerry L. Butler
                                          Title   President
---------------------------------               --------------------------------

                                          Date
                                                --------------------------------

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                                                         PAGE 16

<PAGE>   17

                                    Exhibit A

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/200,724 may be viewed as U.S. Patents Nos. 5,849,868 and 5,858,786 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   18

                                    Exhibit B

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/064,024 may be viewed as U.S. Patent No. 5,708,139 at www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   19

                                    Exhibit C

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/475,775 may be viewed as U.S. Patents Nos. 5,859,324 and 5,776,889 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   20

                                    Exhibit D

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/484,358 may be viewed as U.S. Patents Nos. 5,850,015 and 6,001,959 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   21

                                   Exhibit E
                         Licensed Biological Materials

[*].

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   22
                                AMENDMENT TO THE
                           EXCLUSIVE LICENSE AGREEMENT

             BETWEEN EDEN BIOSCIENCE AND CORNELL RESEARCH FOUNDATION
                  WHICH WAS EFFECTIVE THE FIRST DAY OF MAY 1995

               THIS AMENDMENT (effective as of the first day of February 1997)
to that Exclusive License Agreement referenced above, by and between CORNELL
RESEARCH FOUNDATION, INC., having offices at Cornell Business & Technology Park,
20 Thornwood Drive, Suite 105, Ithaca, New York 14850, hereinafter referred to
as "FOUNDATION" and EDEN BIOSCIENCE CORPORATION, having offices at 5795 N.E.
Minder, Poulsbo, Washington 98370, hereinafter referred to as "LICENSEE".

                                WITNESSETH THAT:

               WHEREAS, FOUNDATION and LICENSEE have previously entered into the
Exclusive License Agreement (effective date of 1 May 1995) which this Amendment
is attached thereto, in which FOUNDATION granted certain exclusive rights in
several patentable technologies developed at Cornell University to LICENSEE; and

               WHEREAS, FOUNDATION and LICENSEE mutually agree that said
Exclusive License Agreement should be modified to include additional patentable
technologies to those described in said Exclusive License Agreement; and

               WHEREAS, FOUNDATION and LICENSEE also agree that said Exclusive
License Agreement should be modified as defined hereinbelow; and

               NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth, the parties hereto hereby agree as follows:

PRIMACY OF AMENDMENT

               The parties agree that the terms and conditions of this Amendment
shall take precedence over those contained in the Exclusive License Agreement.

WHEREAS

               The Whereas clauses of the Exclusive License Agreement shall be
entirely replaced with the following:

               WHEREAS, United States Patent Application No. 08/200,724 entitled
"Elicitors of the Hypersensitive Response in Plants" (CRF D-1172), was filed in
the U.S. Patent & Trademark Office on February 2, 1994, a copy of which is
appended as Exhibit A and

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   23
Patent Application No. 08/200,724 is a continuation of U.S. Patent Application
No. 07/907,935 filed on 1 September 1992 and the foreign equivalent
PCT/US93/06243 was filed on 30 June 1993 covering all EPC countries and Japan;
and

               WHEREAS, United States Patent Application No. 08/062,024 entitled
"Pseudomonas Syringae pv. syringae hrpz Gene" (CRF D-1425), was filed in the
U.S. Patent & Trademark Office on 17 May 1993, a copy of which is appended as
Exhibit B and the foreign equivalent PCT/US94/05014 was filed on 5 May 1994
covering all EPC countries and Japan; and

               WHEREAS, United States Patent Application No. 08/475,775,
entitled "Hypersensitive Response Induced Resistance in Plants" (CRF D-1654),
was filed in the U.S. Patent & Trademark Office on 7 June 1995, a copy of which
is appended as Exhibit C and the foreign equivalent PCT/US96/08819 was filed on
5 June 1996 covering all EPC countries and Japan; and

               WHEREAS, United States Patent Application No. 08/484,358,
entitled "Hypersensitive Response Elicitor From Erwinia Crysanthemi" (CRF
D-1732), was filed in the U.S. Patent & Trademark Office on 7 June 1995, a copy
of which is appended as Exhibit D; and

               WHEREAS, FOUNDATION intends to file a United States Patent
application entitled "Harpin Seed Treatment," now Invention Disclosure CRF
D-1940, a copy of which is appended as Exhibit E, and FOUNDATION intends to file
foreign equivalents, where appropriate, of said Invention Disclosure; and

               WHEREAS, FOUNDATION intends to file a United States Patent
Application entitled [*], Now Invention Disclosure [*], a copy of which is
appended as Exhibit F. and FOUNDATION intends to file foreign equivalents, where
appropriate, of said Invention Disclosure; and

               WHEREAS, FOUNDATION intends to file a United States Patent
Application entitled "Fragments of Harpin," now Invention Disclosure CRF D-1956,
a copy of which is appended as Exhibit G. and FOUNDATION intends to file foreign
equivalents, where appropriate, of said Invention Disclosure; and

               WHEREAS, FOUNDATION intends to file a United States Patent
Application entitled "Enhancement of Plant Growth By Harpin," now Invention
Disclosure CRF D-2018, a copy of which is appended as Exhibit H. and FOUNDATION
intends to file foreign equivalents, where appropriate, of said Invention
Disclosure; and

               WHEREAS, FOUNDATION intends to file a United States Patent
Application entitled "Harpin Results in Reduced Insect Larval Feeding on
Plants," now Invention Disclosure CRF D-2028, a copy of which is appended as
Exhibit I, and FOUNDATION intends to file foreign equivalents, where
appropriate, of said Invention Disclosure; and

               WHEREAS, the inventions disclosed and claimed in Exhibits A, B.
C, D, E, F. G. H and I are, or will be assigned to FOUNDATION and FOUNDATION is
a wholly owned subsidiary corporation of Cornell University and holds the
ownership interests of patents issued on inventions made by Cornell University's
staff and

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                       -2-
<PAGE>   24
administers licenses in a manner consistent with the patent policy of Cornell
University; and

               WHEREAS, FOUNDATION represents that it is, or will be assignee of
the above-identified patent applications and any patents issuing thereon and has
the right to grant licenses under said patent applications and patents issuing
thereon; and

               WHEREAS, the work leading to the inventions disclosed and to be
claimed in Exhibits A, B. C, D, E, F. G. H and I were supported in part by an
agency of the U.S. Government, FOUNDATION is obligated to comply with the U.S.
Office of Management & Budgets Circular No. A124, or 37 CFR Part 401; and

               WHEREAS, Drs. Steven Beer, Alan Collmer and their colleagues at
Cornell University have developed proprietary biological materials and processes
relating to the field of plant disease and some of these materials and processes
are or will be claimed and covered in said patent applications of Exhibits A, B.
C, D, E, F. G. H and I and other such materials and processes are not claimed in
said patent applications but are proprietary to FOUNDATION; and

               WHEREAS, LICENSEE is desirous of securing a license under the
discoveries and inventions embodied in said patent applications and patents
issuing thereon as well as the discoveries and inventions embodied in said
related proprietary biological processes and materials to make, have made, use
and sell Licensed Products in the United States and throughout the world; and

               WHEREAS, FOUNDATION is willing to grant a license in said patent
applications and any patents issuing thereon as well as the discoveries and
inventions embodied in said related proprietary biological processes and
materials to LICENSEE upon the terms and conditions hereinafter set forth; and

               NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth, the parties hereto hereby agree as follows:

DEFINITIONS

               The Definitions section (I) of the Exclusive License Agreement
shall be entirely replaced-with the following:

               1. LICENSED PATENT APPLICATION shall mean U.S. Patent Application
Serial No. 08/200,724 attached as Exhibit A and any continuation,
continuation-in-part, or divisional applications thereof as well as foreign
counterparts thereof and U.S. Patent Application Serial No. 08/062,024 attached
as Exhibit B and any continuation, continuation in-part, or

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                       -3-
<PAGE>   25
               divisional applications thereof as well as foreign counterparts
               thereof and U.S. Patent Application Serial No. 08/475,775
               attached as Exhibit C and any continuation, continuation-in-part,
               or divisional applications thereof as well as foreign
               counterparts attached as Exhibit D and any continuation,
               continuation in-part, or divisional applications thereof as well
               as foreign counterparts thereof and any U.S. Patent Application
               based on Invention Disclosure CRF D-1940 attached as Exhibit E
               and any continuations continuation in-part, or divisional
               applications thereof as well as foreign counterparts thereof and
               any U.S. Patent Application based on Invention Disclosure [*]
               attached as Exhibit F and any continuation, continuation in-part,
               or divisional applications thereof as well as foreign
               counterparts thereof and any U.S. Patent Application based on
               Invention Disclosure CRF D-1956 attached as Exhibit G and any
               continuation, continuation in-part, or divisional applications
               thereof as well as foreign counterparts thereof and any U.S.
               Patent Application based on Invention Disclosure CRF D-2018
               attached as Exhibit H and any continuation, continuation in-part,
               or divisional applications thereof as well as foreign
               counterparts thereof and any U.S. Patent Application based on
               Invention Disclosure CRF D-2028 attached as Exhibit I and any
               continuation, continuation in-part, or divisional applications
               thereof as well as foreign counterparts thereof.

            2. LICENSED PATENT shall mean any U.S. Patents issuing from a
               Licensed Patent Application, and all reissues thereof as well as
               foreign counterparts thereof.

            3. LICENSED BIOLOGICAL MATERIAL shall mean that biological
               material including genes, proteins and peptide fragments,
               expression systems, cells and antibodies developed in the Cornell
               University Laboratories of Drs. Steven Beer, Alan Collmer and
               their colleagues and which is directly related to the inventions
               described in Licensed Patents or Licensed Patent Applications and
               which is listed and described in Exhibit J or added to Exhibit J
               at a later time by written mutual agreement of the parties.
               FOUNDATION and LICENSEE acknowledge that, to the best of their
               knowledge, said list of Exhibit J is complete. Licensed Products
               shall mean any product or use claimed in a Licensed Patent
               Application or Licensed Patent or any product or use which
               incorporates or otherwise utilizes Licensed Biological Material.

            5. LICENSE YEAR shall mean each twelve (12) month period
               beginning on the Effective Date of this Agreement first written
               above and thereafter on the anniversary date thereof.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -4-
<PAGE>   26
            6. LICENSEE shall mean the above named company and any of its
               affiliates in which it owns or controls at least 50% of the
               voting stock..

            7. NET SALES PRICE shall mean [*]

FUTURE INVENTIONS

               The following new section is added to the May 1995 Exclusive
License Agreement:

               "Inventions" or "future inventions" shall refer to those
inventions and discoveries, made subsequent to the Effective Date of the May 95
Exclusive License Agreement, which are technologically related to Licensed
Patent Applications or Licensed Patents or which arise from research at Cornell
University funded by LICENSEE and which are:

               a) made solely by employees of Cornell University; or

               b) made jointly by employees of Cornell University.

               Future inventions made solely by employees of Cornell University
shall be the sole property of FOUNDATION.

               Future inventions made solely by employees of LICENSEE shall be
the sole property of LICENSEE and LICENSEE shall have no obligation to
FOUNDATION with regard to such property.

               Future inventions which are made jointly by employees of Cornell
University and LICENSEE shall be the joint property of FOUNDATION and LICENSEE.

               FOUNDATION and LICENSEE agree to notify each other, in a timely
manner, in writing, of any future inventions. FOUNDATION and LICENSEE shall
cooperate to determine inventorship of such inventions but final determination
of inventorship shall be made by that patent counsel responsible for prosecuting
License Applications or other patent counsel mutually agreed upon by the
parties.

               Disposition of the rights in future inventions shall be
determined based on inventorship, LICENSEE'S funding of the research at Cornell
which produced the

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -5-
<PAGE>   27
               invention and the relationship of potential patent claims of the
               invention to the claims of Licensed Patents or Licensed Patent
               Applications according to the following scheme:

               1.0 FUTURE INVENTION MADE SOLELY BY CORNELL INVENTORS USING
                   LICENSEE'S FUNDING SHALL BE DISPOSED OF AS FOLLOWS:

                   1.1 If the potential patent claims of such invention would be
                       dominated by claims of Licensed Patent Applications or
                       Licensed Patents, FOUNDATION shall, at the request of
                       LICENSEE, and subject to FOUNDATION'S obligations to
                       third parties, add such invention to the Licensed Patent
                       Applications of the May 95 Exclusive License Agreement.

                   1.2 If the potential patent claims of such invention would
                       not be dominated by claims of Licensed Patent
                       Applications or Licensed Patents, FOUNDATION shall,
                       subject to FOUNDATION'S obligations to third parties,
                       grant LICENSEE a first right of refusal on an exclusive
                       license under mutually agreeable terms.

               2.0 FUTURE INVENTION MADE SOLELY BY CORNELL INVENTORS BUT NOT
                   USING LICENSEE'S FUNDING OF CORNELL RESEARCH SHALL BE
                   DISPOSED OF AS FOLLOWS:

                   2.1 If the potential patent claims of such invention would be
                       dominated by claims of Licensed Patent Applications or
                       Licensed Patents, FOUNDATION shall, at the request of
                       LICENSEE, and subject to FOUNDATION'S obligations to
                       third parties, grant LICENSEE a first right of refusal on
                       a license under mutually agreeable terms.

                   2.2 If the potential patent claims of such invention would
                       not be dominated by claims of Licensed Patent
                       Applications or Licensed Patents, LICENSEE shall have no
                       inherent rights therein and disposition of such invention
                       would be solely at FOUNDATION'S discretion.

               3.0 FUTURE INVENTIONS THAT ARE JOINTLY MADE BY EMPLOYEES OF
                   CORNELL AND LICENSEE IN WHICH THE CORNELL PORTION WAS MADE
                   USING LICENSEE'S FUNDING OF CORNELL RESEARCH SHALL BE
                   DISPOSED OF AS FOLLOWS:

                   3.1 If the potential patent claims of such invention would be
                       dominated by claims of Licensed Patent Applications or
                       Licensed Patents, FOUNDATION shall, at the request of
                       LICENSEE, and subject to

               [*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED
               PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY
               WITH THE COMMISSION.

                                      -6-
<PAGE>   28
                       FOUNDATION'S obligations to third parties, add such
                       invention to the Licensed Patent Applications of the May
                       95 Exclusive License Agreement.

                   3.2 If the potential patent claims of such invention would
                       not be dominated by claims of Licensed Patent
                       Applications or Licensed Patents, FOUNDATION shall,
                       subject to FOUNDATION'S obligations to third parties,
                       grant LICENSEE a first right of refusal on an exclusive
                       license under mutually agreeable terms.

               4.0 FUTURE INVENTIONS THAT ARE JOINTLY MADE BY EMPLOYEES OF
                   CORNELL AND LICENSEE IN WHICH THE CORNELL PORTION WAS NOT
                   MADE USING LICENSEE'S FUNDING OF CORNELL RESEARCH SHALL BE
                   DISPOSED OF AS FOLLOWS:

                   4.1 If the potential patent claims of such invention would be
                       dominated by claims of Licensed Patent Applications or
                       Licensed Patents, FOUNDATION shall, at the request of
                       LICENSEE, and subject to FOUNDATION'S obligations to
                       third parties, grant LICENSEE a first right of refusal to
                       a license under mutually agreeable terms.

                   4.2 If the potential patent claims of such invention would
                       not be dominated by claims of Licensed Patent
                       Applications or Licensed Patents, FOUNDATION shall,
                       subject to FOUNDATION'S obligations to third parties,
                       grant LICENSEE a first right of refusal on a license
                       under mutually agreeable terms.

               PAYMENTS MADE IN CONSIDERATION OF THE EXECUTION OF THIS LICENSE
                   AGREEMENT

                   On page 9, section IV of the May 95 Exclusive License
               Agreement, subparagraph 6) shall be followed by an additional
               subparagraph 7) as follows:

                   7)  In the event LICENSEE develops or acquires technology
                       which could avoid the equity vesting schedule described
                       above, such equity shall then fully vest in FOUNDATION
                       without regard to the milestone schedule described
                       hereinabove.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -7-
<PAGE>   29

                                    EXHIBITS

               The Exhibits of the Exclusive License Agreement have been
          expanded and renumbered as follows:

            Exhibit A:  CRF D-1172, US Patent Application No. 08/200,724
                        "Elicitors of the Hypersensitive Response in Plants"

            Exhibit B   CRF D-1425, US Patent Application No. 08/062,024
                        "Pseudomonas Syringae pv. syringae hrpz Gene"

            Exhibit C   CRF D-1654, US Patent Application No. 08/475,775
                        "Hypersensitive Response Induced Resistance in Plants"

            Exhibit D   CRF D-1732, US Patent Application No. 08/484,358
                        "Hypersensitive Response Elicitor From Erwinia
                        Crysanthemi

            Exhibit E   CRF D-1940, US Patent Application No. (TBA)
                        "Harpin Seed Treatment"

            Exhibit F    [*]

            Exhibit G    CRF D-1956, US Patent Application No. (TBA)
                         "Fragments of Harpin"

            Exhibit H    CRF D-2018, US Patent Application No. (TBA)
                         "Enhancement of Plant Growth by Harpin"

            Exhibit I    CRF D-2028, US Patent Application No. (TBA)
                         "Harpin Results In Reduced Insect Larval Feeding
                         On Plants"

            Exhibit J    Licensed Biological Material

               IN WITNESS WHEREOF, the parties have caused this instrument to be
          executed in duplicate as of the day and year first above written.

          ATTEST:                     CORNELL RESEARCH FOUNDATION, INC.

                                      By    /s/ Richard S. Cahoon
-------------------------               ----------------------------------------
                                            Richard S. Cahoon
                                      Title Vice President
                                           -------------------------------------
                                      Date
                                          --------------------------------------

ATTEST:                               EDEN BIOSCIENCE CORPORATION

                                      By    /s/ Jerry L. Butler
-------------------------               ----------------------------------------
                                      Name  Jerry L. Butler
                                          --------------------------------------
                                      Title President
                                           -------------------------------------
                                      Date
                                          --------------------------------------

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                       -8-
<PAGE>   30

                                    Exhibit A

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/200,724 may be viewed as U.S. Patents Nos. 5,849,868 and 5,858,786 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   31

                                    Exhibit B

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/064,024 may be viewed as U.S. Patent No. 5,708,139 at www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   32

                                    Exhibit C

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/475,775 may be viewed as U.S. Patents Nos. 5,859,324 and 5,776,889 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   33

                                    Exhibit D

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/484,358 may be viewed as U.S. Patents Nos. 5,850,015 and 6,001,959 at
www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   34

                                    Exhibit E

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
08/984,207 may be viewed as PCT Publication No. WO 98/24297 at
www.pctgazette.wipo.org or www.patents.ibm.com.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   35
                                   Exhibit F

[*].

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   36

                                    Exhibit G

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
09/086,118 may be viewed as PCT Publication No. WO 98/32844 at
www.pctgazette.wipo.org or www.patents.ibm.com.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   37

                                    Exhibit H

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
09/013,587 may be viewed as PCT Publication No. WO 98/54214 at
www.pctgazette.wipo.org or www.patents.ibm.com.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   38

                                    Exhibit I

In accordance with Rule 202 of Regulation S-T, this exhibit is being filed in
paper pursuant to a continuing hardship request. U.S. Patent Application No.
09/030,270 may be viewed as U.S. Patent No. 5,977,060 at www.uspto.gov.

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   39
                                   Exhibit J
                          Licensed Biological Material

[*].

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   40
                                AMENDMENT TO THE
                          EXCLUSIVE LICENSE AGREEMENT

            between Eden Bioscience and Cornell Research Foundation
                 which was effective the first day of May 1995

     THIS AMENDMENT (effective as of the first day of October 1998) to that
Exclusive License Agreement referenced above (hereinafter the "Agreement"), by
and between CORNELL RESEARCH FOUNDATION, INC., having offices at Cornell
Business & Technology Park, 20 Thornwood Drive, Suite 105, Ithaca, New York
14850, hereinafter referred to as "FOUNDATION" and EDEN BIOSCIENCE CORPORATION,
having offices at 11816 N. Creek Parkway, Bothell, Washington 98011-8205,
hereinafter referred to as "LICENSEE."

                        W I T N E S S E T H   T H A T :

     WHEREAS, FOUNDATION and LICENSEE have previously entered into the
Agreement, effective 1 May 1995, to which this Amendment shall become a part
thereof, in which FOUNDATION granted certain exclusive rights in several
patentable technologies developed at Cornell University to LICENSEE; and

     WHEREAS, FOUNDATION and LICENSEE mutually agree that the Agreement should
be modified such that the Licensed Patent Applications and Licensed Patents of
the Agreement shall be expanded to include the additional Licensed Patent
Applications listed in Exhibit 1 and any patent applications or patents which
derive therefrom including any divisional, continuation, continuations-in-part,
reissues and foreign equivalents thereof, which list may be modified from time
to time; and

     WHEREAS, FOUNDATION and LICENSEE also agree that the Agreement should be
further modified as defined hereinbelow; and

     NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth, the parties hereto hereby agree as follows:

                              PRIMACY OF AMENDMENT

     The parties agree that the terms and conditions of this Amendment shall
take precedence over those contained in the Agreement.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   41
                                  DEFINITIONS

     The Definitions section (1) of the Agreement shall be entirely replaced
with the following:

     1.   LICENSED PATENT APPLICATION shall mean those Licensed Patent
          Applications of the Agreement as well as those U.S. Patent
          Applications listed in Exhibit 1 and any regular, continuation,
          continuation-in-part, or divisional applications thereof as well as
          foreign counterparts thereof as well as any future modifications to
          Exhibit 1 by mutual written agreement of the parties.

     2.   LICENSED PATENT shall mean any U.S. Patents issuing from a Licensed
          Patent Application, and all reissues thereof as well as foreign
          counterparts thereof.

     3.   LICENSED BIOLOGICAL MATERIAL shall mean that biological material
          including genes, proteins and peptide fragments, expression systems,
          cells and antibodies developed in the Cornell University Laboratories
          of Drs. Steven Beer, Alan Collmer and their colleagues and which is
          directly related to the inventions described in Licensed Patents or
          Licensed Patent Applications and which is listed and described in
          Exhibit 2 or added to Exhibit 2 at a later time by written mutual
          agreement of the parties. FOUNDATION and LICENSEE acknowledge that, to
          the best of their knowledge, said list of Exhibit 2 is complete as of
          the Effective Date.

     4.   LICENSED PRODUCTS shall mean any product or use claimed in a Licensed
          Patent Application or Licensed Patent or any product or use which
          incorporates or otherwise utilizes Licensed Biological Material.

     5.   LICENSE YEAR shall mean each twelve (12) month period beginning on
          the Effective Date of this Agreement first written above and
          thereafter on the anniversary date thereof.

     6.   LICENSEE shall mean the above named company and any of its affiliates
          in which it owns or controls at least 50% of the voting stock.

     7.   NET SALES PRICE shall mean [*]

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -2-
<PAGE>   42
     8.   [*] shall mean [*] and any regular continuation,
continuation-in-part, or divisional applications thereof as well as foreign
counterparts thereof. Title to such patents and patent applications is held by
FOUNDATION.

                                     GRANT

     The following paragraph shall be appended to the Grant, Section II on page
6 of the Agreement:

     FOUNDATION also hereby grants to LICENSEE the non-exclusive, royalty-free
right to [*]

                               FUTURE INVENTIONS

     The following new section is added to the Agreement:

     "Inventions" or "future inventions" shall refer to those inventions and
discoveries, made subsequent to the Effective Date of the Agreement, which are
related to the gene cluster map of Exhibit 3 or to Licensed Patent Applications
or Licensed Patents or which arise from research at Cornell University funded
by LICENSEE and which are:

     a)   made solely by employees of Cornell University; or

     b)   made jointly by employees of Cornell University.

     Future inventions made solely by employees of Cornell University shall be
the sole property of FOUNDATION.

     Future inventions made solely by employees of LICENSEE shall be the sole
property of LICENSEE and LICENSEE shall have no obligation to FOUNDATION with
regard to such property.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -3-
<PAGE>   43
     Future inventions which are made jointly by employees of Cornell
University and LICENSEE shall be the joint property of FOUNDATION and LICENSEE.

     If either FOUNDATION or LICENSEE conclude that an invention may fall
within the terms of this Agreement, FOUNDATION and LICENSEE agree to notify
each other, in a timely manner, in writing, of any such future inventions.
FOUNDATION and LICENSEE shall cooperate to determine inventorship of such
inventions but final determination of inventorship shall be made by that patent
counsel responsible for prosecuting Licensed Patent Applications or other
patent counsel mutually agreed upon by the parties. FOUNDATION agrees to
maintain as confidential, all information of LICENSEE which is provided to
FOUNDATION for said purpose of determining inventorship and which is clearly
marked as confidential.

     Disposition of the rights in future inventions shall be determined based
on inventorship, LICENSEE's funding of the research at Cornell which produced
the invention and the relationship of potential patent claims of the invention
to the claims of Licensed Patents or Licensed Patent Applications according to
the following scheme.

1.0  Future invention made solely by Cornell inventors using LICENSEE's funding
     shall be disposed of as follows:

     1.1  If the potential patent claims of such invention would be dominated by
          claims of Licensed Patent Applications or Licensed Patents, FOUNDATION
          shall, at the request of LICENSEE, and subject to FOUNDATION's
          obligations to third parties, add such invention to the Licensed
          Patent Applications of the May 1995 Exclusive License Agreement.

     1.2  If the potential patent claims of such invention would not be
          dominated by claims of Licensed Patent Applications or Licensed
          Patents, FOUNDATION shall, subject to FOUNDATION's obligations to
          third parties, grant LICENSEE a first right of refusal on an exclusive
          license under mutually agreeable terms.

2.0  Future invention made solely by Cornell inventors but not using LICENSEE'S
     funding of Cornell research shall be disposed of as follows:

     2.1  If the potential patent claims of such invention would be dominated by
          claims of Licensed Patent Applications or Licensed Patents, FOUNDATION
          shall, at the request of LICENSEE, and subject to

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -4-

<PAGE>   44
          FOUNDATION's obligations to third parties, grant LICENSEE a first
          right of refusal on a license under mutually agreeable terms.

     2.2  If the potential patent claims of such invention would not be
          dominated by claims of Licensed Patent Applications or Licensed
          Patents, LICENSEE shall have no inherent rights therein and
          disposition of such invention would be solely at FOUNDATION'S
          discretion.

3.0  Future inventions that are jointly made by employees of Cornell and
     LICENSEE in which the Cornell portion was made using LICENSEE's funding of
     Cornell research shall be disposed of as follows:

     3.1  If the potential patent claims of such invention would be dominated by
          claims of Licensed Patent Applications or Licensed Patents, FOUNDATION
          shall, at the request of LICENSEE, and subject to FOUNDATION's
          obligations to third parties, add such invention to the Licensed
          Patent Applications of the May 95 Exclusive License Agreement.

     3.2  If the potential patent claims of such invention would not be
          dominated by claims of Licensed Patent Applications or Licensed
          Patents, FOUNDATION shall, SUBJECT TO FOUNDATION'S obligations to
          third parties, grant LICENSEE a first right of refusal on an exclusive
          license under mutually agreeable terms.

4.0  Future inventions that are jointly made by employees of Cornell and
     LICENSEE in which the Cornell portion was not made using LICENSEE's
     funding of Cornell research shall be disposed of as follows:

     4.1  If the potential patent claims of such invention would be dominated by
          claims of Licensed Patent Applications or Licensed Patents, FOUNDATION
          shall, at the request of LICENSEE, and subject to FOUNDATION's
          obligations to third parties, grant LICENSEE a first right of refusal
          to a license under mutually agreeable terms.

     4.2  If the potential patent claims of such invention would not be
          dominated by claims of Licensed Patent Applications or Licensed
          Patents, FOUNDATION shall, subject to FOUNDATION's obligations to
          third parties, grant LICENSEE a first right of refusal on a license
          under mutually agreeable terms.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -5-

<PAGE>   45
                     PAYMENTS MADE IN CONSIDERATION OF THE
                      EXECUTION OF THIS LICENSE AGREEMENT

     On page 7, section IV of the Agreement, the second paragraph shall be
replaced entirely with the following paragraph:

          It is understood by the parties that FOUNDATION shall take no
          management role in LICENSEE.

     Notwithstanding the equity vesting provisions and schedule defined in
Section IV of the Agreement, the parties hereby agree that the full amount of
equity in LICENSEE owed to FOUNDATION, shall fully and immediately vest in
FOUNDATION upon execution of this Amendment.

                   ROYALTIES AND MINIMUM ROYALTIES TO BE PAID
                          DURING THE LICENSE AGREEMENT

     The language of Section VIII of the Agreement notwithstanding, the parties
agree to modify the royalty terms as follows:

     LICENSEE shall pay to the FOUNDATION a royalty of [*] of the Net Sales
     Price of Licensed Products. However, LICENSEE may request an adjustment in
     said future royalty and, if LICENSEE can justify the need for such
     adjustment, FOUNDATION shall consider such adjustment, although it shall
     have no obligation to do so. Further, the royalty on any transgenic
     Licensed Product shall be determined on a case-by-case basis BY FOUNDATION
     and LICENSEE such that LICENSEE's ability to profitably make, use and sell
     such transgenic Licensed Product shall not be unduly impaired and, in any
     event, such royalty on said transgenic Licensed Product shall not exceed
     [*]. The parties acknowledge the value of LICENSEE's continued support of
     research conducted at Cornell University and, in consideration of such
     support, FOUNDATION agrees to credit any such monies provided to Cornell
     University beyond the [*] provided to Cornell from 1 May through 30
     April 1999 against any future royalties owed by LICENSEE as described in
     the RESEARCH SUPPORT section, hereinbelow.

     The parties agree that any royalty owned to FOUNDATION by LICENSEE on the
sale of any Licensed Product which is based entirely on a Licensed Patent
Application or Licensed Patent which is jointly owned by FOUNDATION and
LICENSEE, shall be reduced by [*]. If such a Licensed Product is based
partially on a jointly owned Licensed Patent Application or Licensed Patent as
well as on a

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -6-
<PAGE>   46
Licensed Patent Application or Licensed Patent which is solely owned by
FOUNDATION, such royalty owed shall be reduced by [*].

                               DUTY OF DILIGENCE

     The language of Section XII of the Agreement notwithstanding, the parties
agree to modify the terms and conditions of LICENSEE's duty of diligence as
follows:

     LICENSEE's obligation to pursue introduction of transgenic Licensed
     Products has been satisfied by providing unrestricted research support to
     Cornell University of [*] for the period May 1998 through April 1999.

                                RESEARCH SUPPORT

     LICENSEE agrees to provide one year of research support to Cornell
University of an amount not less than [*] beginning in May of 1998. Such money
shall not be creditable against future royalties. However, any such research
support beyond the [*] paid from 1 May 1998 through 30 April 1999 may be
credited against future royalty owed by LICENSEE as described hereinabove.

     IN WITNESS WHEREOF, the parties have caused this instrument to be executed
in duplicate as of the day and year first above written.

ATTEST:                       CORNELL RESEARCH FOUNDATION, INC.

                              By     /s/ Richard S. Cahoon
                                --------------------------------------
                                     Richard S. Cahoon
                              Title: Vice President
-------------------                 ----------------------------------
                              Date:
                                   -----------------------------------

ATTEST:                       EDEN BIOSCIENCE CORPORATION

                              By     /s/ Jerry L. Butler
                                --------------------------------------
                                     Jerry L. Butler
                              Title: President
-------------------                 ----------------------------------
                              Date:
                                   -----------------------------------

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -7-
<PAGE>   47
                                   EXHIBIT 1

     The following U.S. Patent Applications and any regular, divisional,
continuation, continuation-in-part applications and foreign equivalents are
hereby Licensed Patent Applications as defined in the Agreement.

1.      CRF D-1940, US Patent Application No. 08/984,207, filed 12/03/97 as
        "Hypersensitive Response Induced Resistance in Plants by Seed
        Treatment"; Inventors: D. Qui, Z. Wei, S. Beer.

[*]

3.      CRF D-1956, US Patent Application No. (TBA: derived from provisional
        No. 60/048,109 filed 05/30/97), filed on 5/28/98 as "Hypersensitive
        Response Elicitor Fragments Eliciting a Hypersensitive Response and
        Uses Thereof"; Inventors: R. Laby, S. Beer, A Collmer, Z. Wei.

4.      CRF D-2018, US Patent Application No. (TBA: derived from provisional
        patent application no. 60/036,048), filed on 1/26/98 as "Enhancement of
        Plant Growth By Harpin"; Inventors: D. Qiu, Z. Wei, S. Beer.

5.      CRF D-2028, US Patent Application No. (TBA: derived from provisional
        patent application no. 60/039,226), filed on ??/??/98 as "Insect
        Control With a Hypersensitive Response Elicitor"; Inventors: T. Zitter,
        Z. Wei.

[*]

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -8-

<PAGE>   48

                                   EXHIBIT 2

[*].

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -9-

<PAGE>   49
                                   EXHIBIT 3

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   50

                                   AMENDMENT 3
                                       TO

                               CORNELL UNIVERSITY
                          OFFICE OF SPONSORED PROGRAMS

                               AGREEMENT NO. 28574

SCHEDULE

        The purpose of this Amendment is to extend the Subcontract period for an
additional period of performance beginning May 1, 1996 and ending April 30,
1999; and, to increase the estimated cost by [*] from [*] to [*]. This
Amendment consists of the Schedule which is made a part of this Amendment for
all purposes

CHANGES

Replace Article 4, with:

        4.     Period of Performance. The Period of performance of this
               Agreement will be May 1, 1996 through April 30, 1999.

Replace Article 6, with:

        6.     Cost and Payments:

               6.1    It is agreed to and understood by the parties that the
                      University shall be reimbursed for all costs incurred in
                      connection with the Project up to the amount of [*] (the
                      "Project Cost"). It is estimated that the amount
                      designated as the Project Cost is sufficient to support
                      Project expenses.

               6.2    The Sponsor shall not be liable for any payment in excess
                      of the Project Cost unless this Agreement is modified in
                      writing. Within ninety (90) days after the termination of
                      this Agreement the University shall submit a final
                      financial report setting forth costs incurred. The report
                      shall be accompanied by a check in the amount, if any, of
                      the excess of funds advanced over costs incurred.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                       -1-
<PAGE>   51

               6.3    All checks shall be made payable to Cornell University and
                      sent to the address specified in Article 19, Notices.
                      Payment shall be made by the Sponsor according to the
                      following schedule.

                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]

Except as modified above, all terms and conditions of the Subcontract shall
remain unchanged and in full force and effect.

IN WITNESS WHEREOF, the parties have cause these presents to be executed in
duplicate on the dates indicated below.

UNIVERSITY                                   EDEN BIOSCIENCE CORP.

/s/ Jeff Bugliari                            /s/ Jerry L. Butler
-----------------------------------          -----------------------------------
Grant and Contract Officer                   Jerry L. Butler President and CEO

               7/22/98                                      8/7/98
-----------------------------------          -----------------------------------
Date                                         Date

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -2-
<PAGE>   52

                                 AMENDMENT NO. 4
                                       TO

                               CORNELL UNIVERSITY
                          OFFICE OF SPONSORED PROGRAMS

                               AGREEMENT NO. 28574

SCHEDULE

        The purpose of this Amendment is to extend the Subcontract period for an
additional period of performance beginning May 1, 1996 and ending April 30,
2000; and to increase the estimated cost by [*] increasing the total
Subcontract to [*].

CHANGES

Replace Article 4 with:

        4.     Period of Performance. The period of performance of this
               agreement will be May 1, 1996 through April 30, 2000.

Replace Article 6 with:

        6.     Cost and Payments:

               6.1    It is agreed to and understood by the parties that the
                      University shall be reimbursed for all costs incurred in
                      connection with the Project up to the amount of [*] (the
                      "Project Cost"). It is estimated that the amount
                      designated as the Project Cost is sufficient to support
                      Project expenses.

               6.2    The Sponsor shall not be liable for any payment in excess
                      of the Project Cost unless this Agreement is modified in
                      writing. Within 90 days after the termination of this
                      Agreement, the University shall submit a final financial
                      report setting forth costs incurred. The report shall be
                      accompanied by a check in the amount, if any, of the
                      excess of funds advanced over costs incurred.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -1-
<PAGE>   53

               6.3    All checks shall be made payable to Cornell University and
                      sent to the address specified in Article 19, Notices.
                      Payment shall be made by the Sponsor according to the
                      following schedule.

                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]
                     [*]                                   [*]

Except as modified above, all terms and conditions of the Subcontract shall
remain unchanged and in full force and effect.

IN WITNESS WHEREOF, the parties have caused these presents to be executed in
duplicate on the dates indicated below

UNIVERSITY                                   EDEN BIOSCIENCE CORP.

/s/ John T. Desch                            /s/ Jerry L. Butler
-----------------------------------          -----------------------------------
John T. Desch                                Jerry L. Butler
Sr. Grant and Contract Officer               President

               4/22/99                                      4/22/99
-----------------------------------          -----------------------------------
Date                                         Date

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -2-
<PAGE>   54

                                 AMENDMENT NO. 5
                                       TO

                               CORNELL UNIVERSITY
                          OFFICE OF SPONSORED PROGRAMS

                               AGREEMENT NO. 28574

SCHEDULE

        The purpose of this Amendment is to extend the Subcontract period for an
additional period of performance beginning May 1, 1996 and ending April 30,
2001; and to increase the estimated cost by [*], increasing the total
Subcontract to [*].

CHANGES

Replace Article 4 with:

        4      Period of Performance

               The period of performance of this agreement will be May 1, 1996
               through April 30, 2001.

Replace Article 6 with:

        6.     Cost and Payments

               6.1    It is agreed to and understood by the parties that the
                      University shall be reimbursed for all costs incurred in
                      connection with the Project up to the amount of [*] (the
                      "Project Cost"). It is estimated that the amount
                      designated as the Project Cost is sufficient to support
                      Project expenses.

               6.2    The Sponsor shall not be liable for any payment in excess
                      of the Project Cost unless this Agreement is modified in
                      writing. Within 90 days after the termination of this
                      Agreement, the University shall submit a final financial
                      report setting forth costs incurred. The report shall be
                      accompanied by a check in the amount, if any, of the
                      excess of funds advanced over costs incurred.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

<PAGE>   55

               6.3    All checks shall be made payable to Cornell University and
                      sent to the address specified in Article 19, Notices.
                      Payment shall be made by the Sponsor according to the
                      following schedule.

                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]
                      [*]                                  [*]

        Except as modified above, all terms and conditions of the Subcontract
shall remain unchanged and in full force and effect.

        IN WITNESS WHEREOF, the parties have caused these presents to be
executed in duplicate on the dates indicated below.

CORNELL UNIVERSITY                           EDEN BIOSCIENCE CORP.

/s/ John T. Desch                            /s/ Jerry L. Butler
-------------------------------------        -----------------------------------
Name:  John T. Desch                         Name:  Jerry L. Butler
Title: Sr. Grant and Contract Officer        Title: President and CEO
       Office of Sponsored Programs

               4/17/2000                                    4/10/2000
-------------------------------------        -----------------------------------
Date                                         Date

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

                                      -2-
<PAGE>   56
                 [CORNELL RESEARCH FOUNDATION, INC. LETTERHEAD]

                                  July 2, 2000

Mr. Jerry Butler
President and CEO
Eden Bioscience Corporation
11816 North Creek Parkway
Bothell, WA   98011-8205

        RE:    OUR REF: [*] - Beer et al.
               LICENSE AMENDMENT
               TO THE EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN EDEN BIOSCIENCE
               CORPORATION AND CORNELL RESEARCH FOUNDATION EFFECTIVE MAY 1, 1995
               AND AMENDED OCTOBER 1, 1998 (HEREINAFTER "LICENSE")

        Effective the first day of June, 2000, the undersigned parties agree
that this Amendment hereby modifies the License as follows:

        "The provisional patent application [*] entitled [*] invented by
David Bauer and Steven Beer and assigned to Cornell Research Foundation was
filed in the United States Patent and Trademark Office on [*] and said
application is hereby added to the list of "Licensed Applications."

        Notwithstanding the grant of rights conveyed to Eden Bioscience
Corporation in the License, Cornell Research Foundation retains the right to
license third parties the right to make, use and sell products covered by said
provisional patent application.

        IN WITNESS THEREOF, the parties have caused this instrument to be
executed in duplicate as of the day and year of the last signature below.

Cornell Research Foundation, Inc.            Eden Bioscience Corporation

      /s/ Richard S. Cahoon                             /s/ J. Butler
-----------------------------------          -----------------------------------
By    Richard S. Cahoon                      By        J. Butler
  ---------------------------------            ---------------------------------
Title   Vice President                       Title        President
     ------------------------------               ------------------------------
Date     June 2, 2000                        Date        June 23, 2000
     ------------------------------               ------------------------------

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
<PAGE>   57
                 [CORNELL RESEARCH FOUNDATION, INC. LETTERHEAD]

                                  July 2, 2000

Mr. Jerry Butler
President and CEO
Eden Bioscience Corporation
11816 North Creek Parkway
Bothell, WA   98011-8205

        RE:    OUR REF: [ * ] - Beer et al.
               LICENSE AMENDMENT
               TO THE EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN EDEN BIOSCIENCE
               CORPORATION AND CORNELL RESEARCH FOUNDATION EFFECTIVE MAY 1, 1995
               AND AMENDED OCTOBER 1, 1998 (HEREINAFTER "LICENSE")

        Effective the first day of June, 2000, the undersigned parties agree
that this Amendment hereby modifies the License as follows:

        "The provisional patent application [ * ] entitled [ * ] invented by
David Bauer and Steven Beer and assigned to Cornell Research Foundation was
filed in the United States Patent and Trademark Office on [ * ] and said
application is hereby added to the list of "Licensed Applications."

        IN WITNESS THEREOF, the parties have caused this instrument to be
executed in duplicate as of the day and year of the last signature below.

Cornell Research Foundation, Inc.            Eden Bioscience Corporation

      /s/ Richard S. Cahoon                             /s/ J. Butler
-----------------------------------          -----------------------------------
By    Richard S. Cahoon                      By        J. Butler
  ---------------------------------            ---------------------------------
Title   Vice President                       Title        President
     ------------------------------               ------------------------------
Date     June 2, 2000                        Date        June 23, 2000
     ------------------------------               ------------------------------

[ * ] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]